title: Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.
abstract: OBJECTIVE
  To compare safety of salmeterol and salbutamol in treating asthma.
  
  
  METHODS
  Double blind, randomised clinical trial in parallel groups over 16 weeks.
  
  
  METHODS
  General practices throughout the United Kingdom.
  
  
  METHODS
  25,180 patients with asthma considered to require regular treatment with bronchodilators who were recruited by their general practitioner (n = 3516).
  
  
  METHODS
  Salmeterol (Serevent) (50 micrograms twice daily) or salbutamol (200 micrograms four times a day) randomised in the ratio of two patients taking salmeterol to one taking salbutamol. All other drugs including prophylaxis against asthma were continued throughout the study.
  
  
  METHODS
  All serious events and reasons for withdrawals (medical and non-medical) whether or not they were considered to be related to the drugs.
  
  
  RESULTS
  Fewer medical withdrawals due to asthma occurred in patients taking salmeterol than in those taking salbutamol (2.91% v 3.79%; chi 2 = 13.6, p = 0.0002). Mortality and admissions to hospital were as expected. There was a small but non-significant excess mortality in the group taking salmeterol and a significant excess of asthma events including deaths in patients with severe asthma on entry. Use of more than two canisters of bronchodilator a month was particularly associated with the occurrence of an adverse asthma event.
  
  
  CONCLUSIONS
  Treatment over 16 weeks with either salmeterol or salbutamol was not associated with an incidence of deaths related to asthma in excess of that predicted. Overall control of asthma was better in patients allocated to salmeterol. Serious adverse events occurred in patients most at risk on entry and were probably due to the disease rather than treatment.
authors.affiliation: Glaxo Group Research, Greenford, Middlesex.
authors.forename: W
authors.initials: W
authors.lastname: Castle
authors.forename: R
authors.initials: R
authors.lastname: Fuller
authors.forename: J
authors.initials: J
authors.lastname: Hall
authors.forename: J
authors.initials: J
authors.lastname: Palmer
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D000068299:Salmeterol Xinafoate; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000420:Albuterol